Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse

• ClinicalTrials.gov Identifier: NCT01311778
• Recruitment Status: Completed
• First Posted: March 10, 2011
• Last Update Posted: March 22, 2013
• Sponsor: Hurd,Yasmin, Ph.D.
• Information provided by (Responsible Party): Yasmin Hurd, Hurd,Yasmin, Ph.D.

Study Description

Brief Summary:

Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value.

Condition or disease	Intervention/treatment	Phase
Opiate Addiction	Drug: Cannabidiol; Drug: Fentanyl	Phase 1

Detailed Description:

Opioid abuse is a significant global public health problem. Of the over million opiate-dependent subjects today, only less than a quarter of such individuals receive treatment. Pharmacotherapeutic approaches traditionally have targeted 5 opioid receptors since heroin and its metabolites bind with highest affinity to this receptor subtype. Although such treatment strategies have improved substance abuse outcomes, they do not effectively block opiate craving and thus are still associated with high rates of relapse. Using a strategy of indirectly regulating neural systems to modulate opioid-related behavior, our preclinical rodent studies consistently demonstrated that cannabidiol (CBD), a nonpsychoactive component of cannabis, specifically inhibited cue- induced heroin-seeking behavior. CBD's selective effect on drug-seeking behavior was pronounced after 24 hrs and endured even two weeks after the last drug administration following short-term CBD exposure. The fact that drug craving is generally triggered by exposure to conditioned cues suggests that CBD might be an effective treatment for heroin craving, specially given its protracted impact on behavior. CBD has already been shown in various clinical studies to be well tolerated with a wide safety margin in human subjects. CBD thus represents a strong candidate for the development as a potential therapeutic agent in humans for opioid craving and relapse prevention. It is the goal of this exploratory phase of the project to (1) determine the safety and basic pharmacokinetic characteristics of CBD when administered concomitantly with opiate in humans and (2) characterize the acute (24 hr) and short-term (3 days) effects of CBD administration on cue-induced craving in drug-abstinent heroin-dependent subjects using a random double blind design. This exploratory investigation together with ongoing complementary preclinical rodent studies has the potential to significantly impact the development of a novel agent for drug relapse prevention that is critical for ending the continued cycle of substance abuse. PUBLIC HEALTH RELEVANCE: Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 18 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Cannabidiol as Treatment Intervention for Opioid Relapse
• Study Start Date: February 2010
• Actual Primary Completion Date: October 2011
• Actual Study Completion Date: October 2011

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; Subjects will receive placebo	Drug: Fentanyl; All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2); Other Name: Fentanyl Citrate
Experimental: CBD 400 mg; Subjects will receive 400 mg CBD	Drug: Cannabidiol; Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl. Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.; Drug: Fentanyl; All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2); Other Name: Fentanyl Citrate
Experimental: CBD 800mg; Subjects will receive 800 mg CBD	Drug: Cannabidiol; Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl. Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.; Drug: Fentanyl; All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2); Other Name: Fentanyl Citrate

Outcome Measures

Primary Outcome Measures :

1. To determine the safety of cannabidiol oral administration prior to fentanyl IV administration. [ Time Frame: 9 timepoints: -10 min, 30, 60, 90, 120, 180, 240, 360, 480 ]
   We will assess safety and adverse effects with the Systematic Assessment for Treatment Emergent Events (SAFTEE). Excessive sedation (GCS<10), cardiac dysrhythmia (on telematry monitor), hypotension (blood pressure < 90/60 mmHg), bradycardia (heart rate 50/minute),severe anxiety, or seizures (partial or generalized tonic-clonic) after the administration of either Fentanyl or Cannabidiol would result in discontinuation of the study for the subject and immediate medical attention.

Secondary Outcome Measures :

1. General cannabidiol pharmacokinetics [ Time Frame: 9 timepoints: -10 min, 30, 60, 90, 120, 180, 240, 360, 480 ]
   Blood will be taken at specified times to determine cannabidiol peak plasma concentration (Cmax), time to reach peak serum concentration (tmax) and serum elimination half-life (t1/2).
2. Cortisol levels [ Time Frame: -10 min, 30, 60, 90, 120, 180, 240, 360, 480 ]
   Variation in plasma levels of cortisol will be measured at various time points.
3. Cannabidiol clearance [ Time Frame: 5 timepoints: -60 min, 45, 120, 240, 480 ]
   Urine will be taken at specified times to estimate cannabidiol concentration in order to assess clearance and excretion functions.
4. Vital signs-BP [ Time Frame: -10, 30, 60, 75, 90, 120, 180, 240, 360, 480 min ]
   Blood pressure (mmHg) will be monitored and change from baseline will be studied across the multiple time points.
5. Vital signs-HR [ Time Frame: -10, 30, 60, 75, 90, 120, 180, 240, 360, 480 min ]
   Heart rate (beats/minute) will be monitored and change from baseline will be studied across the multiple time points.
6. Vital signs - RR [ Time Frame: -10, 30, 60, 75, 90, 120, 180, 240, 360, 480 min ]
   respiratory rate (respirations/minute) will be monitored and change from baseline will be studied across the multiple time points.
7. Vital signs - O2 [ Time Frame: -10, 30, 60, 75, 90, 120, 180, 240, 360, 480 min ]
   % oxygen saturation will be monitored and change from baseline will be studied across the multiple time points.
8. Vital signs - temp [ Time Frame: -10, 30, 60, 75, 90, 120, 180, 240, 360, 480 min ]
   body temperature (degrees Fahrenheit) will be monitored and change from baseline will be studied across the multiple time points.
9. Vital signs - EKG [ Time Frame: -10, 30, 60, 75, 90, 120, 180, 240, 360, 480 min ]
   EKG will be monitored and change from baseline will be studied across the multiple time points.
10. Subjective measures-VAS [ Time Frame: -1, 30, 65, 90, 120, 240, 360, 480 min. ]
    Questionnaires will be used to measure subjective responses. Anxiety will be assessed using a visual analog scale (VAS).
11. Subjective measures-PANAS [ Time Frame: -1, 30, 65, 90, 120, 240, 360, 480 min. ]
    Questionnaires will be used to measure subjective responses. The PANAS (Positive and Negative Affect Schedule) will allow obtaining positive and negative affect measures.
12. Subjective measures-Opiate effect [ Time Frame: -1, 30, 65, 90, 120, 240, 360, 480 min. ]
    Questionnaires will be used to measure subjective responses. Global Intoxication and Withdrawal Rating will be administered to assess potential variations in the subjective effects associated to fentanyl.
13. Subjective measures- OVAS [ Time Frame: -1, 30, 65, 90, 120, 240, 360, 480 min. ]
    Questionnaires will be used to measure subjective responses. Opiate Visual Analog Scales (OVAS) will be administered to assess potential variations in the subjective effects associated to fentanyl.

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• being aged between 21 and 65 years old.
• having exposure at least once to an opioid (i.e. codeine, morphine, Fentanyl) in the past

Exclusion Criteria:

• using any psychoactive drug or medication at any time during the study, or 24 hours before the test session
• having a past or current diagnosis of drug abuse or dependence (except for nicotine), based on the SCID-IV interview (Structured Clinical Interview for DSM-IV)
• being maintained on methadone or buprenorphine, or taking opioid antagonist such as naltrexone
• having taken any opioid in the last 14 days
• having medical conditions, including Axis I psychiatric conditions under DSM-IV (examined with the MINI International Neuropsychiatric Interview-MINI), history of cardiac disease, arrhythmias, head trauma, and seizures
• having a history of hypersensitivity to any opioid or cannabinoid
• being pregnant or breastfeeding
• not using an appropriate method of contraception such as hormonal contraception (oral hormonal contraceptives, Depo-Provera, Nuva-Ring), intrauterine device (IUD), sterilization, or double barrier method (combination of any two barrier methods used simultaneously, i.e. spermicide, diaphragm)
• arriving to the study site visibly intoxicated as determined by a clinical evaluation for signs and symptoms of intoxication and as verified by a drug screen for cocaine, cannabis, opiates, benzodiazepines, barbiturates, phencyclidine and amphetamines
• being actively treated and currently involved in an addiction treatment program
• being an anesthesiologist or a pharmacist

Contacts and Locations

Locations

United States, New York

Mount Sinai Medical Center

New York, New York, United States, 10029

Sponsors and Collaborators

Hurd,Yasmin, Ph.D.

Investigators

• Principal Investigator: Yasmin Hurd, PhD; Icahn School of Medicine at Mount Sinai

More Information

• Responsible Party: Yasmin Hurd, Principal Investigator, Hurd,Yasmin, Ph.D.
• ClinicalTrials.gov Identifier: NCT01311778
• Other Study ID Numbers: R21DA027781 ( U.S. NIH Grant/Contract )
• First Posted: March 10, 2011
• Last Update Posted: March 22, 2013
• Last Verified: March 2013

Additional relevant MeSH terms:

Opioid-Related Disorders; Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Fentanyl; Cannabidiol; Analgesics, Opioid; Narcotics; Central Nervous System Depressants; Physiological Effects of Drugs; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Adjuvants, Anesthesia; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Anticonvulsants